 | Up a level |
Neary, M 
ORCID: 0000-0002-4960-2139, Lamorde, M, Olagunju, A ORCID: 0000-0002-6588-5749, Darin, KM, Merry, C, Byakika-Kibwika, P, Back, DJ, Siccardi, M ORCID: 0000-0002-3539-7867, Owen, A ORCID: 0000-0002-9819-7651 and Scarsi, KK
(2017)
The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 102 (3).
pp. 529-536.
Olagunju, A ORCID: 0000-0002-6588-5749, Rajoli, Rajith KR ORCID: 0000-0002-6015-5712, Atoyebi, Shakir Adeyinka, Khoo, Saye ORCID: 0000-0002-2769-0967, Owen, Andrew and Siccardi, Marco ORCID: 0000-0002-3539-7867
(2018)
Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding.
AAS Open Research, 1 (16).
16-.
Olagunju, A ORCID: 0000-0002-6588-5749
(2019)
Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies.
European Journal of Pharmaceutical Sciences.
Olagunju, A
(2019)
Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies.
European Journal of Pharmaceutical Sciences.